What Is Amylin?
Amylin (also called islet amyloid polypeptide, or IAPP) is a hormone co-secreted with insulin from pancreatic beta cells. Where insulin acts largely on nutrient uptake and storage, amylin is studied as a satiety and gastric-emptying signal: in research models it is associated with reduced food intake, slowed gastric emptying, and modulation of glucagon. It acts centrally, in brain regions such as the area postrema and hypothalamus.
Native amylin is difficult to study directly because it is prone to aggregation and has a very short half-life. This is the problem that engineered amylin analogs are designed to solve.
Cagrilintide: A Long-Acting Amylin Analog
Cagrilintide is a modified amylin analog engineered for stability and a long duration of action. Sequence modifications reduce the aggregation tendency of native amylin, and a lipid (fatty-diacid) side chain promotes reversible albumin binding, which greatly extends its circulating half-life in research models compared with native amylin.
In studied mechanism, Cagrilintide acts as an agonist across the amylin receptor family — receptors formed when the calcitonin receptor pairs with receptor-activity-modifying proteins (RAMPs) to form AMY1, AMY2, and AMY3 — and at the calcitonin receptor itself. Research associates this non-incretin, satiety-signaling pathway with reduced food intake in models, mechanistically separate from how GLP-1 receptor agonists work.
- Amylin analog engineered against aggregation, with a fatty-acid chain for albumin binding and a long half-life.
- Agonist at amylin receptors (AMY1–3, calcitonin receptor + RAMPs) and the calcitonin receptor.
- Studied for central satiety signaling — a pathway distinct from incretin (GLP-1) signaling.
Why Amylin And GLP-1 Are Studied Together
Because amylin and GLP-1 act through different receptors and different circuits, research frequently examines them in combination to study whether the effects on satiety and metabolic signaling are additive or complementary. The combination of Cagrilintide with the GLP-1 agonist Semaglutide (studied under the research name CagriSema) is the most prominent example of this dual-pathway approach in the metabolic literature.
For researchers, the practical point is that amylin analogs open a second, mechanistically independent lever alongside the GLP-1 and GIP pathways covered elsewhere in this library.
Research Context And Handling
Cagrilintide research uses in vitro receptor-binding and cAMP signaling assays for amylin and calcitonin receptors, alongside preclinical feeding and metabolic models. As with every Research Use Only compound, identity and purity should be verified from the Certificate of Analysis, storage should follow the peptide’s stability profile, and findings should be read against the primary literature. The compound is supplied strictly for laboratory research and is not for human or animal use.
Research Use Only: This guide is informational and describes research-context handling of compounds intended strictly for in vitro laboratory research. Products are not for human or animal consumption, ingestion, or injection, and are not FDA-approved. Nothing here is medical, clinical, or dosing advice.
Frequently Asked Questions
What is Cagrilintide?
Cagrilintide is a long-acting amylin analog engineered against aggregation and given a fatty-acid chain for albumin binding to extend its half-life. It is studied as an agonist at amylin receptors and the calcitonin receptor.
How does amylin research differ from GLP-1 research?
Amylin and GLP-1 act through different receptors and circuits. Amylin analogs like Cagrilintide signal satiety through amylin/calcitonin receptors, a pathway mechanistically separate from GLP-1 receptor agonists such as Semaglutide.
What is CagriSema?
CagriSema is the research combination of Cagrilintide (an amylin analog) with Semaglutide (a GLP-1 receptor agonist), studied to examine complementary satiety and metabolic signaling. All such compounds are for in vitro Research Use Only.